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“Absence of evidence is not the same as evidence of 
absence.”
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Some data from Oman
 Prevalence of CKD in Oman: 0.9% of Oman population has CKD stage IV 
and V, 9% has CKD stage III and more than 29% has CKD stage II
 ~ 2000 + patients on HD
 ~ 180 + patients on PD
 22 satellite dialysis units 
 ~ 1500 + patients had at least 1 kidney transplantation
The structures, processes and related outcomes of clinical pharmacy 
practice as part of the multidisciplinary care of patients with CKD
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The 3 phase of the doctoral research
Phase 1: Systematic review
To critically appraise, synthesize and present the available 
evidence
Phase 2: Survey
To determine the behaviours and experiences of UK 
pharmacists providing care to patients with CKD in 
relation to the structures, processes and related outcomes
Phase 3: Interviews
To explore the development, implementation and 
evaluation of pharmacist prescribing for patients with 
Chronic Kidney Disease (CKD) in the UK
Systematic review
Questions:
 What clinical pharmacy practice related resources are in place and how 
are these matched to healthcare needs and demands to enable provide 
care to CKD patients?
 What activities are performed to care for patients with CKD, how and 
when are they performed? 
 What are the outcomes of the structure and the processes on the 
effectiveness and efficiency of care provided? 
Develop research 
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Data extraction and 
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protocol
Steps for conducting the systematic review
Wright et al. 2007
Phase 2: A theoretically based cross-sectional survey on the behaviours 
and experiences of clinical pharmacists on provision of multidisciplinary 
care of patients with chronic kidney disease in the United Kingdom.
Why based on theory?
Which theory?
What is CFIR and why used?
Consolidated Framework For 
Implementation Research
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Results
 71 responses (50% response rate)
 78% female
 More than 50 % were within age group of 31 – 40 years
 82.8% were NMP
How long have you provided clinical care for patients with CKD?
Characteristics of clinical pharmacy services you provide for IN-PATIENTS 
with CKD 
Area of care Providing 
care n (%)
General pharmaceutical care 56 (87.5)
PC for patients receiving dialysis 54 (84.4)
PC for patients at transplantation 46 (71.9)
Poly-pharmacy review 50 (78.1)
Targeted CKD renal medication review 50 (78.1)
Targeted renal medication review: transplantation 47 (73.4)
Targeted renal medication review: anaemia 42 (65.6)
Targeted renal medication review: vasculitis 44 (68.8)
Targeted renal medication review: hypertension 42 (65.6)
Consulting out-patients with renal complication 46 (71.9)
Consulting out-patients on haemodialysis or peritoneal dialysis 45 (70.3)
Consulting out-patients with mineral bone disease 49 (76.6)
AKI 49 (76.6)
Other roles pharmacists were engaged with:
 Audits/service evaluations/quality improvements 72%
 Care home support 9%
 Academic research 8%
 Providing education/training for other pharmacy staff 91%, other 
healthcare professionals 85%, patients 48%
 Involved in production of in-house guidelines, strategy or policy 
88%
Development and implementation of your CLINICAL PHARMACY 
practice 
Statement Strongly agree Agree 
Neither agree 
nor disagree
Disagree 
Strongly 
disagree 
Missing
n (%) n (%) n (%) n (%) n (%) n (%)
I feel there is a need for more evidence for the benefits of my 
role 
14 (21.9) 25 (39.1) 14(21.9) 6 (9.4) 3 (4.7) 2 (3.1)
I feel that colleagues in other organisations are ahead in 
implementing the role
18 (28.1) 20 (31.3) 16 (25) 6 (9.4) 2 (3.1) 2 (3.1)
I feel I have sufficient time to practise in my role 1 (1.6) 10 (15.6) 5 (7.8) 39 (60.9) 8 (12.5) 1 (1.6)
I feel that I am burdened with having to provide other services 
that take me away from providing care for patient with CKD
16 (25) 26 (40.6) 8 (12.5) 9 (14.1) 4 (6.3) 1 (1.6)
I feel my role as a clinical pharmacist for patients with CKD is 
not fully supported by my organisation
3 (4.7) 14(21.9) 13 (20.3) 26 (40.6) 7 (10.9) 1 (1.6)
Intervention characteristics: 
evidence strength and quality
Outer setting: peer pressure
Inner setting: available 
resources
The actions and views of other members of the multi-disciplinary 
team influence my practice
17 (26.6) 43 (67.2) 2 (3.1) 1 (1.6) 0 (0) 1 (1.6)
Process: opinion leaders 
(social influences):
I am confident in my ability as a member of the 
multidisciplinary team
15 (23.4) 40 (62.5) 5 (7.8) 2 (3.1) 0 (0) 2 (3.1)
Characteristics of individuals: 
self efficacy
Inner setting: available 
resources
Process: opinion leaders 
(social influences):
What is the most rewarding aspect of your role in providing clinical 
pharmacy services to patient with CKD?
“Making a difference 
to the patients and 
providing support for 
them”
“Providing holistic 
medication review for 
patients rather than 
segregated specialities 
review”
“Patient related work. 
Solving pharmaceutical 
problems for patients. 
Looking into clinical 
problems” 
“Patients thank me for 
providing them with 
education and being 
appreciated by other 
members of the renal 
team”
“Working as part of the 
MDT to ensure the best 
outcomes for patients 
and doing patient 
education talks to our 
CKD patient”
“The ability to make a 
change to improve the 
care of our patients”
What do you find most challenging about your role in providing clinical 
pharmacy services to patient with CKD?
“No support from 
management to do more 
in outpatient setting”
“Complexity and 
uniqueness of each patient 
cases”
“Prioritisation of workload-
inpatients, out patients, 
HD, PD, ongoing enquiries, 
audits, education and 
training, staff 
management”
“Lack of training”
“Having renal pharmacy 
recognized as a specialist 
pharmacy service which 
requires adequate funding 
and support”
“Lack of time for service 
development.   Significant 
time spent on reactive 
patient flow activities inc.
work that could be done.   
It is a challenge not to get 
frustrated”
Do you have any additional comments about your role in the care of 
patients with CKD?
“We need a team of 
pharmacy staff to provide 
the service” 
I believe it is a valuable role that 
could be expanded to better 
serve our existing population
Need to use 
technology and other 
innovations better
Pharmacy works best when 
it is professionally 
integrated into the frontline 
and NOT as a support 
service
We have gained insight into an existing service:
1. Help determine the value and the impact of the service
2. Reflect on the pro’s and con’s of the service implementation
3. Support in identifying any need for future changes
We need to be vigilant not to be trapped in false, unwanted results!!
Possible challenges in implementing a new service 
1. Clinical pharmacy services are not straightforward
2. It is always a part of a MDT service (involve others)
3. May change over time depending on situations
4. Will require change in behaviours
5. Outcomes to be measured are not easy
Take home messages
1. Renal service is of importance to our patients
2. To be able to successfully implement the service we need to 
evaluate the implementation by research
3. CFIR could be a roadmap for implementation of a service
4. In order to provide high quality evidence, the research must be 
transparent and rigorous to justify the need of a service
5. If we plan well we can execute any service in a systematic fashion

